1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Phoenix Rising Adds Two New Board Members
Mark Berry introduces the new President of Phoenix Rising, Dr. Gary Solomon, and welcomes Professor Jonathan Edwards to the Phoenix Rising Board of Directors.
Discuss the article on the Forums.

Clinical Trials: testing viral load vs immune markers

Discussion in 'XMRV Testing, Treatment and Transmission' started by Rrrr, Sep 15, 2010.

  1. Rrrr

    Rrrr Senior Member

    Messages:
    1,402
    Likes:
    271
    Clinical Trials: testing viral load vs immune markers

    Dr. Yes wrote this: "The difference between Coffin's approach and Mikovits' is the choice of parameter. Coffin wants to wait til we can accurately monitor viral load, while Mikovits wants to monitor other parameters for which there is already evidence of correlations with symptomology in ME/CFS. A great many clinical trials have been done in a great variety of diseases with no known causative agent; the parameters in these cases are usually clinical ones like those Mikovits suggested, and have sometimes been as simple as functional improvement -- usually with some form of objective measure, of course."

    great quote!

    question: does anyone know what immune markers we'd use in a clinical trial, to gage efficacy of a treatment? something solid so that it can be used instead of viral load.
     
  2. Rrrr

    Rrrr Senior Member

    Messages:
    1,402
    Likes:
    271
    i got this from another thread on this forum. could THIS be the list of immune markers mikovits is thinking of using in any WPI clinical trials?

    Treating cytokine up/down-regulation
    ______

    WPI & NCI Paper

    "Type 1 IFN Pathyway Response to Viral Infection in Chronic Fatigue Syndrome"

    Mikovits,J. Hagen,K. Peterson,D. Stephens,R. Lombardi,V.
    Whittemore Peterson Institute, Reno, NV, USA. Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, MD, USA.

    118 CFS patients
    138 Controls

    Cytokines/Chemokines:

    CFS:

    IL-8: 1045
    MIP-1a: 763
    MIP-1b: 1985
    IL-6: 336
    TNF-a: 148
    IL-1b: 500
    IP-10: 98
    IFN-a: 35
    IL-13: 28
    IL-7 160

    Controls:

    IL-8: 13
    MIP-1a: 91
    MIP-1b: 164
    IL-6: 29
    TNF-a: 13
    IL-1b: 56
    IP-10: 32
    IFN-a: 60
    IL-13: 86
    IL-7: 60

    Guide to Chemokines/Cytokines:

    IL-8: RNase L & CMV activated
    MIP-1a: Elevated in neurodegenerative disease
    MIP-1b: Elevated in neurodegenerative disease
    IL-6: Stimulates chronic inflammation
    TNF-a: Stimulates chronic inflammation
    IL-1b: Stimulates chronic inflammation
    IP-10: Interferon response protein
    IFN-a:Stimulates macrophages and NK cells to elicit an anti viral response
    IL-13: Inhibits inflammatory cytokine production
    IL-7: Stimulates proliferation of B & T lymphocytes & NK cells

    Summary and conclusions:

    Cytokine and Chemokine profiling in combination with machine logic algorythms reveals an inflammatory signature consistent with an over-expression of herpes virus and is useful for diagnosis for CFS
     
  3. Kati

    Kati Patient in training

    Messages:
    2,108
    Likes:
    1,730
    Rrrrr one thing you may not have considered is perhaps Dr Mikovits already knows how to measure viral load but the paper is under review? Research is being slowed down by editors,reviewers and printing process.
     
  4. Rrrr

    Rrrr Senior Member

    Messages:
    1,402
    Likes:
    271
    YES! this is very true.
     

See more popular forum discussions.

Share This Page